Main Article Content
MigraiMigraine is a common and highly disabling neurological disorder, associated with a significant reduction of quality of life and also impact on social functioning. The management of migraine patients is often unsatisfactory because the acute treatment of attacks has been limited to NSAIDs and combination of ergotamine-caffeine. The development of the triptans dramatically improved the acute treatment of migraine attacks. However, some patients do not respond desirably to the medicines and cardiovascular comorbidities limit their usage. Patients with migraine highly need a new therapeutic approach which should have rapid onset, longer duration of action, be better tolerated and lack of vasoconstriction activity. This review focuses on future pharmacological target and compounds which have been developed for the acute attacks of migraine including: serotonin 5-HT1F receptor agonists, nitric oxide synthase inhibitors, calcitonin gene-related peptide (CGRP) receptor antagonists, cation channel subfamily vanilloid member 1 (TRPV1) receptor modulators, glutamate receptors antagonists and PAC1 receptor antagonists. These compounds may be potentially viable anti-migraine drugs in the future.
Upon acceptance of an article, the Pharmacological and Therapeutic Society of Thailand will have exclusive right to publish and distribute the article in all forms and media and grant rights to others. Authors have rights to use and share their own published articles.
Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet. 2010;21;376(9741):645-55.
Chang A, Rapoport AM. Acute treatment of migraine headache. Tech Reg Anesth Pain Manag. 2009;13:9-15.
Dipiro J, Talbert RL, editors. Pharmacotherapy A Pathophysiologic Approach. 3rd ed. Pennsylvania: McGraw-Hill Education; c2014
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache 2015; 55:3.
MaassenVanDenBrink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998;98:25.
Hoffmann J, Goadsby PJ. Emerging Targets in Migraine. CNS Drugs. 2014;28:11–17
Diener HC,Charles A, Goadsby PJ, Holle D. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol. 2015;14:1010–1022
Goadsby PJ, Classey JD. Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003;122: 491–498.
Färkkilä M, Diener HC, Géraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11:405–413.
Basbaum AI, Fields HL. Endogenous pain control mechanisms: review and hypothesis. Ann. Neurol. 1978;4(5):451–462.
Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47(5):614–624.
Lambert GA, Hoskin KL, Zagami AS. Nitrergic and glutamatergic neuronal mechanisms at the trigeminovascular ﬁrst-order synapse. Neuropharmacology. 2004;47(1):92–105.
Lassen LH, Ashina M ,Christiansen I, Ulrich V, Olesen J. Nitric oxide synthase inhibition in migraine. Lancet. 1997;349(9049):401–402.
Olesen J. Nitric Oxide-related drug targets in headache. Neurotherapeutics. 2010;7(2):183–190.
Hoffmann J1, Goadsby PJ. New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors. Curr Treat Options Neurol. 2012;14(1):50-59.
Hougaard A, Hauge A, Guo S, Tfelt-Hansen P. The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: a randomized, double-blind, placebo-controlled cross-over study. Scan J Pain. 2012; 4: 48–52.
Sabato D, Lionetto L and Martelletti P. The therapeutic potential of novel anti-migraine acute therapies. Expert Opin. Investig. Drugs. 2015; 24(2):141-144.
Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23(2):193–196.
Diener HC, Barbanti P, Dahlöf C, Reuter U, Habeck J, Podhorna J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2011; 31: 573–584.
Meng J, Ovsepian SV, Wang J, et al. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci. 2009;29:4981–4992
Tso AR, Goadsby PJ. New targets for migraine therapy. Curr Treat Options Neurol. 2014;16:318
Kayi Chan, Antoinette MaassenVanDenBrink. Glutamate Receptor Antagonists in the Management of Migraine. Drugs. 2014; 74:1165–1176
Vieira DS, Naffah-Mazzacoratti Mda G, Zukerman E, Senne Soares CA, Cavalheiro EA, Peres MF. Glutamate levels in cerebrospinal ﬂuid and triptans overuse in chronic migraine. Headache. 2007;47(6):842–847
Henrik W. Schytz, Jes Olesen, and Messoud Ashina. The PACAP Receptor: A Novel Target for Migraine Treatment. Neurotherapeutics. 2010;7,191–196.